论文部分内容阅读
目的探讨白蛋白结合型紫杉醇治疗晚期乳腺癌患者的近期疗效以及安全性。方法回顾性分析2013年1月至2015年6月期间收治的45例应用白蛋白结合型紫杉醇治疗的晚期乳腺癌患者的临床资料。白蛋白结合型紫杉醇单药化疗剂量260 mg/m~2,静脉滴注30 min,每3周给药1次,无需进行抗过敏预处理。同时给予患者5-羟色胺3(5-HT3)受体拮抗剂以预防化疗药物导致的胃肠道不良反应,并进行补液水化处理。每2个周期评估疗效以及不良反应。结果本组45例患者均顺利完成疗程,平均化疗5.2个周期。所有患者均可评价疗效,其中CR 3例(6.67%),PR 16例(35.56%),SD 24例(53.33%),PD 2例(4.44%),总有效率ORR为42.22%。治疗过程中,主要不良反应包括消化道反应、骨髓抑制、感觉神经异常以及肌肉关节酸痛,Ⅲ~Ⅳ度白细胞减少发生率为53.33%,Ⅲ~Ⅳ度粒细胞减少发生率为40.00%,Ⅲ~Ⅳ度血小板减少(2.22%)以及贫血(8.89%)的发生率较低。结论白蛋白结合型紫杉醇治疗晚期乳腺癌患者可以取得较好的临床效果,且不良反应较少,患者耐受性好,可以推广应用。
Objective To investigate the short-term efficacy and safety of albumin-bound paclitaxel in the treatment of patients with advanced breast cancer. Methods The clinical data of 45 patients with advanced breast cancer treated with albumin-bound paclitaxel between January 2013 and June 2015 were retrospectively analyzed. Albumin-bound paclitaxel monotherapy chemotherapy dose of 260 mg / m ~ 2, intravenous infusion of 30 min, administered once every 3 weeks, without the need for anti-allergic preconditioning. Patients were also given serotonin 3 (5-HT3) receptor antagonist to prevent chemotherapy-induced gastrointestinal adverse reactions, and hydration rehydration. The efficacy and adverse reactions were evaluated every 2 cycles. Results The 45 patients in this group were successfully completed the treatment, the average chemotherapy 5.2 cycles. All of the patients could evaluate the curative effect. CR 3 patients (6.67%), PR 16 patients (35.56%), SD 24 patients (53.33%), PD 2 patients (4.44%), the total effective rate ORR was 42.22%. The main adverse reactions included digestive tract reaction, myelosuppression, sensory nerve abnormality and muscle and joint pain. The incidence of grade Ⅲ ~ Ⅳ leukopenia was 53.33%, the incidence of grade Ⅲ ~ Ⅳ neutropenia was 40.00% Grade IV thrombocytopenia (2.22%) and anemia (8.89%) were associated with a lower incidence. Conclusions Albumin-bound paclitaxel can achieve better clinical outcomes in patients with advanced breast cancer with fewer side effects and patients with good tolerability.